18:42 , Sep 19, 2018 |  BC Extra  |  Preclinical News

Mayo Clinic team implicates senescent cells in neurodegenerative diseases

Clearing out senescent brain cells could prevent tau-mediated neurodegeneration and cognitive loss, although it's still too early to determine whether the approach can halt or reverse disease progression, according to a Nature letter from Mayo...
19:16 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Filgotinib meets in Phase III FINCH 2 study for RA

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said both doses of filgotinib met the primary and all key secondary endpoints in the Phase III FINCH 2 trial to treat rheumatoid arthritis. Filgotinib is...
17:25 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Quantum Leap provides update on I-SPY 2 breast cancer trial

Quantum Leap Healthcare Collaborative provided an update on the overall progress of the Phase II I-SPY 2 trial evaluating neoadjuvant treatments for breast cancer in patients at high risk for early recurrence. Quantum Leap said thus...
22:45 , Sep 13, 2018 |  BC Week In Review  |  Financial News

Galapagos follows positive RA data with $300M round

On the heels of positive Phase III data for rheumatoid arthritis therapy filgotinib, Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) raised $300 million on Sept. 13 through the sale of 2.6 million ADSs at $116.50 on NASDAQ. Morgan...
20:42 , Sep 13, 2018 |  BC Innovations  |  Emerging Company Profile

Mapping tumor markers

BioGraph 55 Inc. is mapping immune cells in the tumor microenvironment to identify cell-to-cell interaction patterns that can help match patients to existing therapies and identify novel therapeutic targets. The newco is developing a pipeline...
05:33 , Sep 13, 2018 |  BC Extra  |  Financial News

Galapagos follows positive RA data with $300M round

On the heels of positive Phase III data for rheumatoid arthritis therapy filgotinib, Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) raised $300 million through the sale of 2.6 million ADSs at $116.50 on NASDAQ. Morgan Stanley, Citigroup, Kempen...
23:32 , Sep 11, 2018 |  BC Extra  |  Clinical News

Filgotinib meets in Phase III FINCH 2 study for RA

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said both doses of filgotinib met the primary and all key secondary endpoints in the Phase III FINCH 2 trial to treat rheumatoid arthritis. Filgotinib is...
19:32 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Acute lung injury Mouse studies suggest inhibiting ZMPSTE24 with Kaletra lopinavir/ritonavir could help treat acute lung injury (ALI). In a mouse model of ventilator-induced ALI, systemic ZMPSTE24 knockout decreased markers of injury and increased oxygenation...
18:33 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Principia seeks IPO ahead of Phase III trials for Btk program

Principia Biopharma Inc. (South San Francisco, Calif.) proposed late Aug. 17 to raise $86.3 million in an IPO on NASDAQ and revealed that it raised $49.7 million in a series C round this month. Underwriters...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Company News

AbbVie exercises option for argenx cancer candidate

AbbVie Inc. (NYSE:ABBV) exercised an option for exclusive, worldwide rights to develop and commercialize ARGX-115 from argenx S.E. (Euronext:ARGX; NASDAQ:ARGX). argenx told BioCentury it has received $60 million from AbbVie thus far under the 2016 deal,...